Corporate Finance, DeFi, Blockchain, Web3 News
Fintech, DeFi, Blockchain, Web3 Daily News by Finyear

Psomagen and Macrogen Granted U.S. Patent for Blockchain Data-sharing Technology

The precision medicine and biotechnology company Macrogen (CEO Kap-Seok Yang, announced on September 17 that it had been granted a U.S. patent for its blockchain-based data-sharing technology. The patent for a ‘data-sharing method based on the plurality of blockchains (patent No. 10417219)’ was jointly filed with the USPTO (United States Patent and Trademark Office) by Psomagen and Macrogen.

The registered U.S. patent is a technology that combines a token economy system with a blockchain platform to facilitate active data sharing and transactions. Using this technology, users who wish to purchase data can easily make payments with a point or token which is automatically distributed to the brokerage platform commission and provider reward by the ‘smart contract’. Individuals who have consented to provide and distribute their data will obtain additional rewards not only for the initial data-sharing process but also for each data transaction thereafter.

Using this technology, the ownership of healthcare and genomic data that hospitals and/or testing institutions had is returned to the individuals. This creates a blockchain-based transaction environment in which data providers directly interact with users. Ultimately, this technology will create an ecosystem where individuals can freely exercise their rights at every stage of the healthcare big data value chain—from generation and storage to searching and utilization.

The healthcare big data distribution platform with this technology not only allows individuals to own and manage their healthcare data but also make profits from data sharing. This system induces the active participation of data providers, creating a virtuous cycle in which larger amounts of high-quality healthcare data are accumulated at a faster pace. In other words, highly useful, high-quality healthcare big data can be collected and integrated more quickly.

Psomagen, which jointly filed the patent with Macrogen, plans to apply the technology to the United States DTC market. The company plans to encourage the voluntary participation of individual users to quickly build high-quality healthcare big data and take the lead in the platform business in the U.S. market.

“The United States is the fastest-growing market in the world for the concept of individual health sovereignty and DTC genetic testing,” said Ryan W. Kim, the CEO of Psomagen. “We expect these market characteristics to help Psomagen’s healthcare big data distribution platform take off quickly, allowing the company to build high-quality healthcare big data in a short time,” he added.

Macrogen’s blockchain data-sharing technology has been registered in Korea in August 2018, followed by a U.S. patent in September 2019. Additional patents are currently pending in Europe, Japan, China, and Singapore.

Meanwhile, according to Kalorama Information and Global Market Insights, the global DTC market is expected to grow to approximately USD 2.5 billion by 2025. The U.S. DTC market, which accounts for 72% of the current DTC market worldwide, is expected to grow to over USD 1.8 billion by 2025.

Macrogen Inc.


Lisez gratuitement le quotidien Finyear & sa newsletter quotidienne.
Recevez chaque matin par mail la newsletter Finyear, une sélection quotidienne des meilleures infos et expertises en finance digitale, corporate finance & crypto finance.

Read for free The daily newspaper Finyear & its daily newsletter.
Receive the Finyear's newsletter every morning by email, a daily snapshot of the best news and expertise in digital finance, corporate finance & crypto finance.


Chaineum :
Fondée en 2015, Chaineum est un cabinet de conseil en opérations de haut de bilan offrant une expertise de premier plan en matière d’ICO et STO, avec une vision stratégique orientée tant vers le métier de ses clients que sur la technologie blockchain. A ce titre, Chaineum a participé à la mise en œuvre de bonnes pratiques dans le secteur (ICO Charter, Security Token Network).
La division services blockchain de Chaineum, développe la technologie Chaineum Segment, une blockchain privée orientée objets.

About Chaineum:
Founded in 2015, Chaineum is a leading corporate finance advisory firm with a strong expertise in ICO and STO, and a strategic focus on both its clients' business and blockchain technology. As such, Chaineum paved the way in the implementation of certain best practices in this sector (ICO Charter, Security Token Network).
Chaineum's blockchain services division, is developing Chaineum Segment technology, an object-oriented private blockchain.


No Offer, Solicitation, Investment Advice, or Recommendations

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor does it constitute an offer to provide investment advisory or other services by FINYEAR.
No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security.
Nothing on this website shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.
Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor.
This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.
Any views expressed on this website by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change.
All information is subject to possible correction. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.

Mercredi 18 Septembre 2019